Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRX-920
- Development stage
- Phase 1
- Lead developer
- TaiRx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TRX-920 is an oral formulation of SN-38, the active metabolite of irinotecan (CPT-11), developed by TaiRx for the treatment of cancer, particularly advanced solid tumors. Unlike irinotecan, which requires metabolic activation in the body to produce SN-38, TRX-920 delivers SN-38 directly via an oral gel formulation. This approach aims to improve anti-tumor efficacy and reduce side effects compared to conventional irinotecan therapy. The drug acts as a DNA topoisomerase I inhibitor—disrupting DNA replication and transcription in cancer cells—and is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors[1][2][4][7].
- Other names
- SN-38 oral gelSN38 oral gelSN 38 oral gelSN-38 encapsulated micelleSN38 encapsulated micelleSN 38 encapsulated micelleSN-38-nanoparticles-Intezyne-TechnologiesSN38-nanoparticles-Intezyne-TechnologiesSN 38-nanoparticles-Intezyne-Technologies
02
Targets
TOP1 (DNA Topoisomerase I)CES2 (Carboxylesterase 2)
Beyond the preview
Go deeper on TRX-920.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRX-920.